Intrexon | XON - Pre Tax Profit


Intrexon reported $-60.48M in Pre-Tax Profit for its fiscal quarter ending in June of 2024.





Pre Tax Profit Change Date
Agenus USD 39.21M 49.82M Mar/2026
Alaunos Therapeutics USD -7.84M 633K Dec/2023
Amgen USD 2.08B 570M Mar/2026
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD -178.9M 41.34M Jun/2026
AstraZeneca USD 4.81B 894M Jun/2026
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Gilead Sciences USD -7.53B 10.11B Jun/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Incyte USD 751.51M 407.91M Jun/2026
Intrexon USD -60.48M 27.09M Jun/2024
Karyopharm Therapeutics USD -22.39M 17.51M Mar/2026
Ligand Pharmaceuticals USD -24.26M 81.04M Mar/2026
MacroGenics USD -36.77M 21.84M Mar/2026
MannKind USD -16.37M 4.56M Mar/2026
Merck USD -3.53B 6.95B Mar/2026
Novartis USD 4.27B 430M Jun/2026
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Roche Holding CHF 11.17B 6.38B Jun/2026
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Thermo Fisher Scientific USD 1.73B 389M Mar/2026
Veracyte USD 26.52M 3.45M Jun/2026
Xencor USD -21.92M 106.72M Jun/2026